OSRH

OSR Holdings Inc

Apr 08 • 04:00PM ET

0.4920

+0.0007 0.14 %

Healthcare • Biotechnology • USA • NASD

Index	-	P/E	-	EPS (ttm)	-1.31	Insider Own	50.98%	Shs Outstand	26.60M	Perf Week	-18.41%
Market Cap	16.30M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	16.24M	Perf Month	-1.93%
Enterprise Value	68.40M	PEG	-	EPS next Q	-	Inst Own	0.52%	Short Float	2.32%	Perf Quarter	-18.00%
Income	-18.01M	P/S	5.60	EPS this Y	-	Inst Trans	-4.83%	Short Ratio	0.23	Perf Half Y	-22.52%
Sales	2.91M	P/B	0.17	EPS next Y	-	ROA	-20.76%	Short Interest	0.38M	Perf YTD	-12.78%
Book/sh	2.92	P/C	9.59	EPS next 5Y	-	ROE	-50.63%	52W High	1.79 -72.51%	Perf Year	-67.20%
Cash/sh	0.05	P/FCF	-	EPS past 3/5Y	-518.53% -214.49%	ROIC	-23.20%	52W Low	0.38 29.37%	Perf 3Y	-95.13%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-299.86%	Volatility	12.72% 13.45%	Perf 5Y	-
Dividend TTM	-	EV/Sales	23.51	EPS Y/Y TTM	-35.85%	Oper. Margin	-631.01%	ATR (14)	0.06	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	0.15	Sales Y/Y TTM	-	Profit Margin	-619.82%	RSI (14)	49.49	Recom	2.00
Dividend Gr. 3/5Y	- -	Current Ratio	0.16	EPS Q/Q	79.20%	SMA20	1.36%	Beta	0.50	Target Price	10.00
Payout	-	Debt/Eq	0.06	Sales Q/Q	-	SMA50	0.22%	Rel Volume	0.47	Prev Close	0.49
Employees	4	LT Debt/Eq	0.00	Earnings	Dec 03	SMA200	-26.76%	Avg Volume	1.62M	Price	0.49
IPO	Mar 17, 2023	Option/Short	No / Yes	EPS/Sales Surpr.	- -	Trades		Volume	765,143	Change	0.14%

Mar-30-26 09:00AM	OSR Holdings to Update Investors at the Emerging Growth Conference on April 1, 2026 (ACCESSWIRE) +13.84%
Mar-27-26 09:00AM	Emerging Growth Research Issues Flash Report on OSR Holdings, Inc., Reaffirms Buy-Emerging Rating and $10.00 Price Target (ACCESSWIRE) +5.57%
Mar-23-26 08:30AM	OSR Holdings Updates $815 Million VXM01 Licensing Deal Structure to Capture Value at Parent Level (ACCESSWIRE) +9.59%
Mar-19-26 09:44AM	Woori IO, an OSR Company, Signs NDA with Sinopharm for China Market and Global Multicenter Trials (PR Newswire)
08:55AM	Woori IO, an OSR Company, Signs NDA with Sinopharm to Explore China Commercial Opportunities (ACCESSWIRE)
09:30AM	Loading…
Mar-05-26 09:30AM	OSR Holdings, Inc. Granted 180-Day Nasdaq Extension; Reaffirms Strategic Momentum (ACCESSWIRE) +14.67%
Feb-02-26 09:50AM	CEO Statement to Shareholders (ACCESSWIRE)
Jan-27-26 08:30AM	OSR Holdings Completes Woori IO Acquisition, Secures Long-Term Shareholder Alignment, and Reviews Strategic Combination of Medical Device Subsidiaries (ACCESSWIRE)
Jan-22-26 09:55AM	Woori IO, an OSR Company, Highlights FDA Clarification on Non-Medical Wearables as a Catalyst for Accelerated Commercial Launch (PR Newswire) +10.23%
Jan-16-26 09:20AM	Vaximm Appoints Sebastien Wieckowski, PhD, as Chief Scientific Officer to Advance Next-Generation Oral Immunotherapy Platform (PR Newswire)
Jan-12-26 08:05AM	Vaximm, an OSR Company, Receives Binding Term Sheet from BCM Europe for Global Exclusive License of VXM01 with $30M Upfront and Up to $815M in Milestones (PR Newswire) +8.26%
Dec-19-25 11:50AM	Woori IO Shareholders Approve Share Exchange to Become Wholly-Owned Subsidiary of OSR Holdings (PR Newswire) +13.65%
Dec-04-25 03:19PM	Emerging Growth Research Issues Flash Report on OSR Holdings, Inc., Reaffirms Buy-Emerging Rating and $10.00 Price Target Following Major Licensing Agreement (Newsfile) +9.99%
Dec-02-25 09:53AM	Vaximm AG, an OSR Company, Updates Term Sheet with BCM Europe to Shorten Exclusivity Period to Three Months (PR Newswire)
Dec-01-25 03:01PM	OSR Holdings to Present at the Emerging Growth Conference on December 10, 2025 (PR Newswire)
09:20AM	Loading…
Nov-21-25 09:20AM	Vaximm AG, an OSR Company, Enters Term Sheet With BCM Europe for Potential VXM01 License with $20M Upfront and Up to $815M in Milestones (PR Newswire) +23.38%
Nov-14-25 11:10AM	OSR Holdings Appoints Scientific Co-Founder Dr. Andreas Niethammer as Chief Executive Officer of Vaximm AG to Lead Next Phase of Immuno-Oncology Expansion (PR Newswire) -8.83%
Nov-06-25 08:30AM	OSR Holdings Announces Woori IO's Noninvasive Glucose Monitor Demonstrates High Accuracy and Precision in Company-Sponsored Pilot Study (PR Newswire) +13.98%
Oct-20-25 11:40AM	Emerging Growth Research Initiates Coverage on OSR Holdings, Inc. with a Buy-Emerging Rating and $10.00 Price Target (Newsfile) +25.67%
Oct-14-25 08:30AM	OSR Holdings Signs Definitive Agreement to Acquire Woori IO, a Pioneer in Noninvasive Glucose Monitoring with Potential to Transform Diabetes Care (PR Newswire)
Sep-09-25 05:30PM	OSR Holdings Receives Nasdaq Minimum Bid Price Deficiency Notice; Company Highlights Unusual Trading Activity (PR Newswire) +9.58%
Aug-25-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) +96.12%
Aug-01-25 01:29PM	OSR Holdings to Host Virtual Investor Event Providing Key Corporate Updates and Strategic Direction on August 6, 2025 (PR Newswire) -6.67%
Jul-31-25 12:45PM	OSR Holdings Provides Transparency Update on Equity Financing Instruments (PR Newswire) -20.44%
Jul-30-25 04:10PM	OSR Holdings Provides Strategic Update on Woori IO Term Sheet and Share Exchange Structure (PR Newswire) -6.99%
Jul-28-25 05:49AM	OSR Holdings to acquire South Koreas medical device company Woori IO (Medical Device Network)
Jul-24-25 07:30AM	OSR Holdings Enters into Term Sheet to Acquire Woori IO, a Pioneer in Noninvasive Glucose Monitoring Technology (PR Newswire) -5.88%
Jul-15-25 07:30AM	OSR Holdings Appoints Dr. Andreas Niethammer as Chief Medical Officer of Vaximm AG, an OSR Company (PR Newswire) -7.02%
Jul-08-25 10:03AM	OSR Holdings Announces Strategic Roadmap for Tokenization Under Reg D Framework in Partnership with BCM Europe AG (PR Newswire)
May-22-25 07:36AM	OSR Holdings, BCM Europe, and Taekwondo Cooperative Announce Strategic MOU to Launch Blockchain-Based OSRH Token (PR Newswire) +5.25%
07:30AM	Loading…
May-02-25 07:30AM	Darnatein to Present at 14th International BMP Conference Highlighting Advances in Regenerative Biologics (PR Newswire)
Apr-09-25 07:54AM	Darnatein, an OSR Company, Broadens Intellectual Property Protection for Innovative Osteoarthritis Treatment Technology (PR Newswire)
Apr-03-25 07:30AM	OSR Holdings, Inc. (NASDAQ: OSRH) Enters Into $80 Million Common Stock Purchase Agreement With White Lion GBM Innovation Fund, With An Eye Towards Leveraging Innovate GBM's Non-Profit Ecosystem to Accelerate Glioblastoma Therapies (PR Newswire) +68.03%
Mar-26-25 07:16AM	Vaximm AG, an OSR Company, Announces Results from Phase 2a Trial of VXM01 and Avelumab Combination Therapy in Glioblastoma (PR Newswire) +136.87%
Mar-25-25 07:00AM	OSR Holdings Appoints Dr. Constance Hfer as Chief Scientific Officer (PR Newswire) -7.51%

OSR Holdings, Inc. operates as a global healthcare company. The firm engages in developing oral immunotherapies for cancer treatment, design-augmented biologics for age-related and other degenerative diseases, and neurovascular intervention of medical devices and systems distribution in Korea. Its products are offered through its subsidiaries. The company was founded on February 25, 2020 and is headquartered in Bellevue, WA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

OSRH

OSR Holdings Inc

Upgrade your Finviz experience